{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:23:51Z","timestamp":1792567431604,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100001368","name":"V foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"crossref"}]},{"name":"PNOC Foundation"},{"DOI":"10.13039\/100001794","name":"Pediatric Brain Tumor Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DIPG Collaborative Foundation","award":["MTX110"],"award-info":[{"award-number":["MTX110"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The objective of this study was to determine the safety, tolerability, and distribution of MTX110 (aqueous panobinostat) delivered by convection-enhanced delivery (CED) in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) who completed focal radiation therapy (RT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with DIPG (2\u201321 years) were enrolled after RT. CED of MTX110 combined with gadoteridol was completed across 7 dose levels (DL) (30\u201390 \u00b5M; volumes ranging from 3 mL to 2 consecutive doses of 6 mL). An accelerated dose escalation design was used. Distribution of infusate was monitored with real-time MR imaging. Repeat CED was performed every 4\u20138 weeks. Quality-of-life (QoL) assessments were obtained at baseline, every 3 months on therapy, and end of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between May 2018 and March 2020, 7 patients who received a total of 48 CED infusions, were enrolled (median age 8 years, range 5\u201321). Three patients experienced dose-limited toxicities. Four grade 3 treatment-related adverse events were observed. Most toxicities were transient new or worsening neurologic function. Median overall survival (OS) was 26.1 months (95% confidence interval: 14.8\u2013not reached). Progression-free survival was 4\u201314 months (median, 7). Cumulative percentage of tumor coverage for combined CED infusions per patient ranged from 35.6% to 81.0%. Increased CED infusions were negatively associated with self-reported QoL assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Repeat CED of MTX110 with real-time imaging with gadoteridol is tolerable for patients with DIPG. Median OS of 26.1 months compares favorably with historical data for children with DIPG. The results support further investigation of this strategy in a larger cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noad105","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T09:40:26Z","timestamp":1686390026000},"page":"2074-2086","source":"Crossref","is-referenced-by-count":60,"title":["PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3452-5150","authenticated-orcid":false,"given":"Sabine","family":"Mueller","sequence":"first","affiliation":[{"name":"Department of Neurology, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Pediatrics, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Neurological Surgery, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Pediatrics, University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7765-7690","authenticated-orcid":false,"given":"Cassie","family":"Kline","sequence":"additional","affiliation":[{"name":"Division of Oncology, Children\u2019s Hospital of Philadelphia , Philadelphia, Pennsylvania , USA"},{"name":"Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1931-7521","authenticated-orcid":false,"given":"Schuyler","family":"Stoller","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9809-1104","authenticated-orcid":false,"given":"Shannon","family":"Lundy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Christopher","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5052-0501","authenticated-orcid":false,"given":"Alyssa T","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Pediatrics, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9657-4839","authenticated-orcid":false,"given":"Anu","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Neurological Surgery, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabitha M","family":"Cooney","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorder Center , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Raber","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0831-4285","authenticated-orcid":false,"given":"Carly","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Luks","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wembacher-Schroeder","sequence":"additional","affiliation":[{"name":"Brainlab AG , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Lummel","sequence":"additional","affiliation":[{"name":"Brainlab AG , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin R","family":"Bonner","sequence":"additional","affiliation":[{"name":"Center for Genetic Medicine Research, Children\u2019s National Medical Center , Washington , DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-9828","authenticated-orcid":false,"given":"Javad","family":"Nazarian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Zurich , Zurich , Switzerland"},{"name":"Center for Genetic Medicine Research, Children\u2019s National Medical Center , Washington , DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9854-7404","authenticated-orcid":false,"given":"Annette M","family":"Molinaro","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9630-2075","authenticated-orcid":false,"given":"Michael","family":"Prados","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Neurological Surgery, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-0757","authenticated-orcid":false,"given":"Javier E","family":"Villanueva-Meyer","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Radiology, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9539-7052","authenticated-orcid":false,"given":"Nalin","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Neurological Surgery, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"5","key":"2023110711241533800_CIT0001","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat Genet."},{"issue":"17","key":"2023110711241533800_CIT0002","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1158\/0008-5472.CAN-14-1298","article-title":"ACVR1 mutations in DIPG: lessons learned from FOP","volume":"74","author":"Taylor","year":"2014","journal-title":"Cancer Res."},{"key":"2023110711241533800_CIT0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fonc.2018.00239","article-title":"Beyond the blood:brain barrier: the importance of central nervous system (CNS) pharmacokinetics for the treatment of CNS tumors, including diffuse intrinsic pontine glioma","volume":"8","author":"Warren","year":"2018","journal-title":"Front Oncol."},{"issue":"2","key":"2023110711241533800_CIT0004","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11060-015-1969-9","article-title":"Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma","volume":"126","author":"Subashi","year":"2016","journal-title":"J Neurooncol."},{"issue":"1","key":"2023110711241533800_CIT0005","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3171\/JNS-07\/07\/0190","article-title":"Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note","volume":"107","author":"Lonser","year":"2007","journal-title":"J Neurosurg."},{"issue":"2","key":"2023110711241533800_CIT0006","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bpa.12082","article-title":"Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations","volume":"24","author":"Barua","year":"2014","journal-title":"Brain Pathol."},{"issue":"3","key":"2023110711241533800_CIT0007","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3171\/2018.9.PEDS17225","article-title":"Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma","volume":"23","author":"Heiss","year":"2018","journal-title":"J Neurosurg Pediatr"},{"issue":"8","key":"2023110711241533800_CIT0008","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(18)30322-X","article-title":"Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial","volume":"19","author":"Souweidane","year":"2018","journal-title":"Lancet Oncol."},{"issue":"4","key":"2023110711241533800_CIT0009","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10147-020-01853-0","article-title":"Clinical experience of convection-enhanced delivery (CED) of carboplatin and sodium valproate into the pons for the treatment of diffuse intrinsic pontine glioma (DIPG) in children and young adults after radiotherapy","volume":"26","author":"Szychot","year":"2021","journal-title":"Int J Clin Oncol."},{"issue":"6","key":"2023110711241533800_CIT0010","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3171\/2020.6.PEDS20280","article-title":"Repeat convection-enhanced delivery for diffuse intrinsic pontine glioma","volume":"26","author":"Bander","year":"2020","journal-title":"J Neurosurg Pediatr"},{"issue":"7","key":"2023110711241533800_CIT0011","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nm0715-827a","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med."},{"issue":"1","key":"2023110711241533800_CIT0012","doi-asserted-by":"crossref","first-page":"e0169485","DOI":"10.1371\/journal.pone.0169485","article-title":"Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models","volume":"12","author":"Hennika","year":"2017","journal-title":"PLoS One."},{"key":"2023110711241533800_CIT0013","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2147\/IJN.S125300","article-title":"Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model","volume":"12","author":"Singleton","year":"2017","journal-title":"Int J Nanomed."},{"key":"2023110711241533800_CIT0014","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2018.10.012","article-title":"Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma","volume":"442","author":"Choi","year":"2019","journal-title":"Cancer Lett."},{"issue":"519","key":"2023110711241533800_CIT0015","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med."},{"issue":"10","key":"2023110711241533800_CIT0016","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/07357907.2021.1983584","article-title":"Phase II study of single-agent and combination everolimus and panobinostat in relapsed or refractory diffuse large B-cell lymphoma","volume":"39","author":"Islam","year":"2021","journal-title":"Cancer Invest."},{"issue":"7","key":"2023110711241533800_CIT0017","doi-asserted-by":"crossref","first-page":"e0270854","DOI":"10.1371\/journal.pone.0270854","article-title":"Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort","volume":"17","author":"Maouche","year":"2022","journal-title":"PLoS One."},{"issue":"3","key":"2023110711241533800_CIT0018","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-021-04313-2","article-title":"Panobinostat penetrates the blood-brain barrier and achieves effective brain concentrations in a murine model","volume":"88","author":"Homan","year":"2021","journal-title":"Cancer Chemother Pharmacol."},{"issue":"4","key":"2023110711241533800_CIT0019","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00280-019-04021-y","article-title":"Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma","volume":"85","author":"Rodgers","year":"2020","journal-title":"Cancer Chemother Pharmacol."},{"issue":"2","key":"2023110711241533800_CIT0020","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3171\/2020.2.PEDS19786","article-title":"High-dose MTX110 (soluble panobinostat) safely administered into the fourth ventricle in a nonhuman primate model","volume":"26","author":"Sandberg","year":"2020","journal-title":"J Neurosurg Pediatr"},{"issue":"3","key":"2023110711241533800_CIT0021","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3171\/2018.2.PEDS17663","article-title":"The distribution, clearance, and brainstem toxicity of panobinostat administered by convection-enhanced delivery","volume":"22","author":"Singleton","year":"2018","journal-title":"J Neurosurg Pediatr"},{"issue":"3","key":"2023110711241533800_CIT0022","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/neuonc\/noq191","article-title":"Temozolomide in the treatment of high-grade gliomas in children: a report from the Children\u2019s Oncology Group","volume":"13","author":"Cohen","year":"2011","journal-title":"Neuro Oncol"},{"issue":"1","key":"2023110711241533800_CIT0023","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.ijrobp.2012.09.004","article-title":"Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children\u2019s oncology group phase 2 study","volume":"85","author":"Bradley","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"2023110711241533800_CIT0024","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","article-title":"The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity","volume":"3","author":"Varni","year":"2003","journal-title":"Ambul Pediatr."},{"issue":"3","key":"2023110711241533800_CIT0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/pbc.21026","article-title":"The PedsQL Brain Tumor Module: initial reliability and validity","volume":"49","author":"Palmer","year":"2007","journal-title":"Pediatr Blood Cancer."},{"issue":"23","key":"2023110711241533800_CIT0026","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1158\/1078-0432.CCR-18-1345","article-title":"Clinically relevant and minimally invasive tumor surveillance of pediatric diffuse midline gliomas using patient-derived liquid biopsy","volume":"24","author":"Panditharatna","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2023110711241533800_CIT0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Soft"},{"issue":"2","key":"2023110711241533800_CIT0028","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J Chiropr Med"},{"key":"2023110711241533800_CIT0029","article-title":"Convection-enhanced delivery of cintredekin besudotox (interleukin-13-Pe38qqr) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results","author":"Vogelbaum","year":"2008","journal-title":"Neurosurgery."},{"issue":"8","key":"2023110711241533800_CIT0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/neuonc\/nop054","article-title":"Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma","volume":"12","author":"Kunwar","year":"2010","journal-title":"Neuro Oncol"},{"issue":"3","key":"2023110711241533800_CIT0031","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1227\/NEU.0b013e3182181ba8","article-title":"Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans","volume":"69","author":"Sampson","year":"2011","journal-title":"Neurosurgery."},{"issue":"8","key":"2023110711241533800_CIT0032","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/mt.2010.114","article-title":"Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors","volume":"18","author":"Su","year":"2010","journal-title":"Mol Ther."},{"issue":"3","key":"2023110711241533800_CIT0033","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3171\/2011.3.JNS101381","article-title":"Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer","volume":"115","author":"Asthagiri","year":"2011","journal-title":"J Neurosurg."},{"issue":"26","key":"2023110711241533800_CIT0034","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 virus for pediatric diffuse intrinsic pontine glioma","volume":"386","author":"Gallego Perez-Larraya","year":"2022","journal-title":"N Engl J Med."},{"issue":"3","key":"2023110711241533800_CIT0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s11060-018-2991-5","article-title":"Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience","volume":"140","author":"Kline","year":"2018","journal-title":"J Neurooncol."},{"key":"2023110711241533800_CIT0036","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2016.12.007","article-title":"Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG\/DIPG working group","volume":"73","author":"Janssens","year":"2017","journal-title":"Eur J Cancer."},{"issue":"1","key":"2023110711241533800_CIT0037","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11060-019-03271-3","article-title":"Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201","volume":"145","author":"Chi","year":"2019","journal-title":"J Neurooncol."},{"issue":"12","key":"2023110711241533800_CIT0038","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1172\/JCI140378","article-title":"Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma","volume":"130","author":"Mueller","year":"2020","journal-title":"J Clin Invest."},{"issue":"18","key":"2023110711241533800_CIT0039","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1158\/1078-0432.CCR-22-0803","article-title":"Upfront biology-guided therapy in diffuse intrinsic pontine glioma: therapeutic, molecular, and biomarker outcomes from PNOC003","volume":"28","author":"Kline","year":"2022","journal-title":"Clin Cancer Res."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noad105\/50897120\/noad105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/11\/2074\/52763559\/noad105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/11\/2074\/52763559\/noad105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T06:25:09Z","timestamp":1699338309000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/25\/11\/2074\/7198341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6,15]]},"published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noad105","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11,1]]},"published":{"date-parts":[[2023,6,15]]}}}